MIMadoka Iida

Madoka Iida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Madoka Iida has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Masahisa Katsuno

    Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan

    8 shared publications
  • Kentaro Sahashi

    Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    3 shared publications
  • Kazunari Onodera

    Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    2 shared publications
  • Kenji Sakakibara

    Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    2 shared publications
  • Kentaro Maeda

    Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    2 shared publications
  • Tomoki Hirunagi

    Nagoya University Graduate School of Medicine, Tokai National Higher Education and Research System 1 Department of Neurology 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550

    2 shared publications

Latest Publications

  • Open Access

    Management of Refractory Thymoma‐Associated Myasthenia Gravis With Sequential FcRn Antagonist and Complement Inhibition Combined With Resection of Pleural Dissemination

    by Hiroyuki Takenaka, Madoka Iida, Yuki Fukami, Masahisa Katsuno

    Myasthenia gravis (MG) associated with disseminated thymoma is often refractory to conventional treatments due to continuous autoantibody production. The optimal treatment strategy, particularly the combination of complement component 5 (C5) inhibitor, neonatal Fc receptor (FcRn) antagonist, and surgical resection in thymoma‐associated myasthenic crisis, remains to be established. A 48‐year‐old man with Masaoka stage IVa thymoma developed an immunotherapy‐resistant myasthenic crisis. He was treated with a neonatal Fc receptor (FcRn) antagonist followed by a complement component 5 inhibitor, alongside repeated surgical resections of pleural implants. This strategy facilitated a persistent decline in anti‐acetylcholine receptor antibody titers and clinical remission despite the persistence of residual tumor. This case suggests that in MG associated with Masaoka stage IVa thymoma and pleural dissemination, the combination of FcRn antagonists, C5 inhibitors, and repeated surgical resection when feasible may contribute to providing an avenue from crisis to long‐term disease control.


  • Open Access

    Restoring early postnatal synaptic dysregulation rescues motor neuron degeneration in a mouse model of Spinal and Bulbar Muscular Atrophy

    by Tomoki Hirunagi, Kentaro Sahashi, Madoka Iida, Kazunari Onodera, Satoshi Yokoi, Yosuke Ogura, Genki Tohnai, Kenji Sakakibara, Kentaro Maeda, C. Frank Bennett, et al.

    Spinal and bulbar muscular atrophy (SBMA) is an adult-onset neurodegenerative disorder caused by expansion of a polyglutamine tract in the androgen receptor (AR). Here, we show that polyglutamine-expanded AR accumulates in the nucleus of motor neurons and induces aberrant upregulation of glutamatergic synaptic genes through dysfunction of the master transcriptional repressor REST during early postnatal development in a mouse model of SBMA (AR-97Q mice). Reducing mutant AR or restoring REST function using antisense oligonucleotides during the neonatal period attenuated the upregulation of glutamatergic synaptic genes and ameliorated the disease phenotype and histopathology in AR-97Q mice. Furthermore, we observed increased calcium activity in induced pluripotent stem cell-derived motor neurons from SBMA patients compared to those from healthy controls, reflecting neuronal hyperexcitability. Late-onset neurodegeneration in SBMA is attributable to early synaptic defects and the resulting hyperexcitability of motor neurons, which may represent therapeutic targets.


  • Open Access

    Bone Fragility and Fracture Characteristics in Patients With Spinal and Bulbar Muscular Atrophy

    by Takahiro Kawase, Shinichiro Yamada, Yoshiyuki Kishimoto, Daisuke Ito, Shota Komori, Ayano Kondo, Madoka Iida, Itaru Kawashima, Yasuhiko Takegami, Atsushi Hashizume, et al.

    Background: Spinal and bulbar muscular atrophy (SBMA) is a hereditary neuromuscular disorder linked to androgen receptor gene mutations, often associated with metabolic abnormalities. We aimed to investigate the incidence of fragility fractures and the underlying mechanisms in SBMA. Methods: Consecutive genetically confirmed SBMA patients and healthy controls (HC) were enrolled. We surveyed fracture history and assessed motor function, bone metabolism markers, and bone mineral density (BMD) using dual‐energy X‐ray absorptiometry. Longitudinal BMD changes were also analyzed between SBMA patients and HC. Results: A total of 109 SBMA patients and 21 HC were included. Fragility fractures in SBMA patients were mainly observed in cortical bone‐dominant regions. Their lower limb BMD was significantly reduced (SBMA 1.10 g/cm, HC 1.19 g/cm; p < 0.05) and further decreased overtime. Despite low bone resorption markers, bone formation markers showed no difference between the groups, suggesting that SBMA patients exhibit characteristics of low turnover osteoporosis. Serum 25‐hydroxyvitamin D levels were lower in SBMA patients than in HC (15.4 ng/mL vs. 19.4 ng/mL; p < 0.01). Longitudinal analysis revealed that SBMA patients had a higher incidence of fragility fractures than HC (log‐rank test, p < 0.05), with the first fragility fracture occurring 10 years after the onset of muscle weakness. Low baseline BMD was a predictor of fragility fractures (adjusted OR = 0.32; 95% CI: 0.17–0.60; p < 0.05). Conclusions: SBMA patients have a high fragility fracture incidence, particularly in cortical bone, with a progressive BMD decrease. Low bone turnover and vitamin D deficiency are associated with these fractures.


  • Open Access

    Label-free morphology-based phenotypic analysis of spinal and bulbar muscular atrophy muscle cell models

    by Kenji Sakakibara, Kenjiro Tanaka, Madoka Iida, Yuta Imai, Mai Okada, Kentaro Sahashi, Tomoki Hirunagi, Kentaro Maeda, Ryuji Kato, Masahisa Katsuno

    Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disorder caused by CAG trinucleotide expansion in the androgen receptor (AR) gene. To improve the quality of in vitro cell-based assays for the evaluation of potential drug candidates for SBMA, we developed a morphology-based phenotypic analysis for a muscle cell model of SBMA that involves multiparametric morphological profiling to quantitatively assess the therapeutic effects of drugs on muscle cell phenotype. The analysis was validated using dihydrotestosterone and pioglitazone, which have been shown to exacerbate and ameliorate the pathophysiology of SBMA, respectively. Gene expression analysis revealed activation of the JNK pathway in the SBMA cells compared to the control cells. Phenotypic analysis revealed the effect of naratriptan, a JNK inhibitor, on the phenotypic changes of SBMA cells, and the results were confirmed by LDH assays. We then trained a predictive machine learning model to classify the drug responses, and it successfully discriminated between pioglitazone-type and naratriptan-type morphological profiles based on their morphological characteristics. Our morphology-based phenotypic analysis provides a noninvasive and efficient screening method to accelerate the development of therapeutics for SBMA.

  • Dysregulation of Aldh1a2 underlies motor neuron degeneration in spinal muscular atrophy

    by Mayumi Kataoka, Kentaro Sahashi, Koyo Tsujikawa, Jun-Ichi Takeda, Tomoki Hirunagi, Madoka Iida, Masahisa Katsuno


  • Open Access

    Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS

    by Tomoki Hirunagi, Kentaro Sahashi, Kiyoshi Tachikawa, Angel I. Leu, Michelle Nguyen, Rajesh Mukthavaram, Priya P. Karmali, Padmanabh Chivukula, Genki Tohnai, Madoka Iida, et al.


  • Open Access

    Immunoprecipitation of protein lysate from culture cells using Src antibody

    by Madoka Iida, Masahisa Katsuno

    It is a procedure for immunoprecipitation using protein lysate from a neuronal cell line, NSC34, and a muscle cell line, C2C12 using DynabeadsTM Protein G Immunoprecipitation Kit (ThermoFisher).

  • Open Access

    Bio-Plex phosphoprotein assay using spinal cords and skeletal muscles of mice

    by Madoka Iida, Masahisa Katsuno

    Bio-Plex phosphoprotein assays are magnetic bead-based immunoassays for the detection of intracellular phosphoproteins in cell and tissue lysates. The assay can be readily multiplexed to simultaneously examine the expression levels of numerous phosphorylated proteins.